Frontier Biotechnologies

Frontier Biotech is a biopharmaceutical company headquartered in Nanjing, China. The company focuses on the research, development, and commercialization of innovative drugs, working to address unmet medical needs in China and other markets. It operates under the Frontier Biotech brand, and its official website is frontierbiotech.com. As a Chinese biotech brand, Frontier Biotech is part of the continued growth of China's life sciences industry. Its operations span drug discovery, clinical development, and manufacturing, and it is one of the domestic players working to bring innovative therapies to patients. The company is headquartered in Nanjing, a city with strong pharmaceutical and academic foundations. Public information about the company in the available evidence is limited, confirming only that it is a company based in Nanjing, China. Further details about its pipeline, ownership, and financial condition are not provided by the current sources.

Frontier Biotechnologies is a biopharmaceutical company located in Nanjing, China. The available evidence confirms its existence as a company in Nanjing but does not provide details on its founding date, founders, or early history. The company operates in China's pharmaceutical and biotechnology sector, which has expanded significantly in recent decades as the country invests in innovative drug development. As a Nanjing-based biotech, Frontier Biotechnologies is part of a regional cluster that includes research institutions and other life sciences firms. The company's focus is on developing and commercializing pharmaceutical products, though specific milestones and product launches are not documented in the current evidence. Without further sourced information, the history of Frontier Biotechnologies remains largely undocumented in this dossier. The company is active and maintains a web presence at frontierbiotech.com.

• 2024

  11 Consecutive Years of Losses and Delayed Annual Report; Channel Inventory Buildup and Revenue Cut Draw Inquiry

  Frontier Biotech's anti-HIV new drug Aikening has fallen short of commercialization expectations; the company has posted losses for 11 consecutive years and delayed disclosure of its 2025 annual report. Because distributor sell-through was below expectations, it reduced revenue by 20.28 million yuan, and the Shanghai Stock Exchange questioned its revenue recognition and channel inventory. It had previously terminated multiple fundraising-backed projects and sold a loss-making subsidiary. Regulatory inquiry.

  Source

Read more

1. 1Frontier Biotechnologies Inc. (China) - Wikidatawikidata.org
2. 211 Consecutive Years of Losses and Delayed Annual Report; Channel Inventory Buildup and Revenue Cut Draw Inquiryfinance.sina.com.cn
3. 311 Consecutive Years of Losses and Delayed Annual Report; Channel Inventory Buildup and Revenue Cut Draw Inquirynews.qq.com